DexCom (NASDAQ:DXCM) Posts Earnings Results, Misses Estimates By $0.05 EPS

DexCom (NASDAQ:DXCM) posted its quarterly earnings data on Thursday. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05), Zacks reports. DexCom had a net margin of 17.22% and a return on equity of 31.40%.

DexCom Price Performance

Shares of DexCom stock opened at $84.09 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm’s 50-day simple moving average is $82.11 and its 200-day simple moving average is $75.19. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The firm has a market cap of $32.85 billion, a P/E ratio of 50.35, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,342 shares of company stock worth $3,628,069. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on DXCM. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. JPMorgan Chase & Co. raised their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Oppenheimer decreased their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and lifted their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.